FR-167356 | CAS#174185-16-1 | vacuolar ATPase Inhibitor

MedKoo Cat#: 525105 | Name: FR-167356

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FR-167356 is a novel inhibitor of vacuolar ATPase. It has been proposed as a drug target in lytic bone diseases. Studies suggest that the key issue regarding the therapeutic usefulness of V-ATPase inhibitors is selective inhibition of osteoclast V-ATPase.

Chemical Structure

FR-167356

CAS#174185-16-1

Theoretical Analysis

MedKoo Cat#: 525105

Name: FR-167356

CAS#: 174185-16-1

Chemical Formula: C19H17Cl2NO3

Exact Mass: 377.0586

Molecular Weight: 378.25

Elemental Analysis: C, 60.33; H, 4.53; Cl, 18.75; N, 3.70; O, 12.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

FR-167356; FR167356; FR 167356; UNII-XF02B1HC8R.

IUPAC/Chemical Name

Benzamide, 2,6-dichloro-N-(3-(1-hydroxy-1-methylethyl)-2-methyl-7-benzofuranyl)-

InChi Key

GCAOVMKRBUCSET-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H17Cl2NO3/c1-10-16(19(2,3)24)11-6-4-9-14(17(11)25-10)22-18(23)15-12(20)7-5-8-13(15)21/h4-9,24H,1-3H3,(H,22,23)

SMILES Code

Cc1c(c2cccc(c2o1)NC(=O)c3c(cccc3Cl)Cl)C(C)(C)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 378.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada GH, Wada Y, Yasui N, Yoneda T. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011 Jul;9(7):845-55. doi: 10.1158/1541-7786.MCR-10-0449. Epub 2011 Jun 13. PubMed PMID: 21669964. 2: Morissette G, Ammoury A, Rusu D, Marguery MC, Lodge R, Poubelle PE, Marceau F. Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. Br J Pharmacol. 2009 Aug;157(8):1531-40. doi: 10.1111/j.1476-5381.2009.00320.x. Epub 2009 Jul 7. PubMed PMID: 19594752; PubMed Central PMCID: PMC2765325. 3: Morissette G, Lodge R, Marceau F. Intense pseudotransport of a cationic drug mediated by vacuolar ATPase: procainamide-induced autophagic cell vacuolization. Toxicol Appl Pharmacol. 2008 May 1;228(3):364-77. doi: 10.1016/j.taap.2007.12.031. Epub 2008 Jan 26. PubMed PMID: 18295291. 4: Niikura K, Takeshita N, Takano M. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005 Sep;20(9):1579-88. Epub 2005 May 31. PubMed PMID: 16059630. 5: Niikura K, Takano M, Sawada M. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol. 2004 Jun;142(3):558-66. Epub 2004 May 17. PubMed PMID: 15148249; PubMed Central PMCID: PMC1574973.